<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10113876</article-id>
    <article-id pub-id-type="pmid">37089814</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcad017</article-id>
    <article-id pub-id-type="publisher-id">zcad017</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resources</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title><bold>HiTAIC: hi</bold>erarchical tumor artificial intelligence classifier traces tissue of origin and tumor type in primary and metastasized tumors using DNA methylation</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9854-5823</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Ze</given-names>
        </name>
        <aff><institution>Department of Epidemiology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
        <aff><institution>Quantitative Biomedical Sciences Program, Guarini School of Graduate and Advanced Studies</institution>, Dartmouth College, <addr-line>Hanover</addr-line>, NH, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1089-9323</contrib-id>
        <name>
          <surname>Lu</surname>
          <given-names>Yunrui</given-names>
        </name>
        <aff><institution>Quantitative Biomedical Sciences Program, Guarini School of Graduate and Advanced Studies</institution>, Dartmouth College, <addr-line>Hanover</addr-line>, NH, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2564-8909</contrib-id>
        <name>
          <surname>Vosoughi</surname>
          <given-names>Soroush</given-names>
        </name>
        <aff><institution>Department of Computer Science</institution>, Dartmouth College, <addr-line>Hanover</addr-line>, NH, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8050-1291</contrib-id>
        <name>
          <surname>Levy</surname>
          <given-names>Joshua J</given-names>
        </name>
        <aff><institution>Department of Epidemiology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
        <aff><institution>Quantitative Biomedical Sciences Program, Guarini School of Graduate and Advanced Studies</institution>, Dartmouth College, <addr-line>Hanover</addr-line>, NH, <country country="US">USA</country></aff>
        <aff><institution>Department of Pathology and Dermatology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3022-426X</contrib-id>
        <name>
          <surname>Christensen</surname>
          <given-names>Brock C</given-names>
        </name>
        <aff><institution>Department of Epidemiology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
        <aff><institution>Quantitative Biomedical Sciences Program, Guarini School of Graduate and Advanced Studies</institution>, Dartmouth College, <addr-line>Hanover</addr-line>, NH, <country country="US">USA</country></aff>
        <aff><institution>Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2279-4097</contrib-id>
        <name>
          <surname>Salas</surname>
          <given-names>Lucas A</given-names>
        </name>
        <!--lucas.a.salas@dartmouth.edu-->
        <aff><institution>Department of Epidemiology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
        <aff><institution>Quantitative Biomedical Sciences Program, Guarini School of Graduate and Advanced Studies</institution>, Dartmouth College, <addr-line>Hanover</addr-line>, NH, <country country="US">USA</country></aff>
        <aff><institution>Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth</institution>, <country country="LB">Lebanon</country>, NH, <country country="US">USA</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +1 603 646 5420; Email: <email>lucas.a.salas@dartmouth.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="epub" iso-8601-date="2023-04-19">
      <day>19</day>
      <month>4</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>19</day>
      <month>4</month>
      <year>2023</year>
    </pub-date>
    <volume>5</volume>
    <issue>2</issue>
    <elocation-id>zcad017</elocation-id>
    <history>
      <date date-type="accepted">
        <day>13</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>04</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>16</day>
        <month>1</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcad017.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Human cancers are heterogenous by their cell composition and origination site. Cancer metastasis generates the conundrum of the unknown origin of migrated tumor cells. Tracing tissue of origin and tumor type in primary and metastasized cancer is vital for clinical significance. DNA methylation alterations play a crucial role in carcinogenesis and mark cell fate differentiation, thus can be used to trace tumor tissue of origin. In this study, we employed a novel tumor-type-specific hierarchical model using genome-scale DNA methylation data to develop a multilayer perceptron model, HiTAIC, to trace tissue of origin and tumor type in 27 cancers from 23 tissue sites in data from 7735 tumors with high resolution, accuracy, and specificity. In tracing primary cancer origin, HiTAIC accuracy was 99% in the test set and 93% in the external validation data set. Metastatic cancers were identified with a 96% accuracy in the external data set. HiTAIC is a user-friendly web-based application through <ext-link xlink:href="https://sites.dartmouth.edu/salaslabhitaic/" ext-link-type="uri">https://sites.dartmouth.edu/salaslabhitaic/</ext-link>. In conclusion, we developed HiTAIC, a DNA methylation-based algorithm, to trace tumor tissue of origin in primary and metastasized cancers. The high accuracy and resolution of tumor tracing using HiTAIC holds promise for clinical assistance in identifying cancer of unknown origin.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <caption>
            <p>HiTAIC is a DNA methylation-based multilayer perceptron classifier that traces the tissue of origin and tumor type in primary and metastatic tumors.</p>
          </caption>
          <graphic xlink:href="zcad017figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Department of Defense</institution>
            <institution-id institution-id-type="DOI">10.13039/100000005</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>W81XWH-20-1-0778</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institute of General Medical Sciences</institution>
            <institution-id institution-id-type="DOI">10.13039/100000057</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>P20GM104416/8299</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute</institution>
            <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R01CA253976</award-id>
        <award-id>R01CA216265</award-id>
        <award-id>R01CA275974</award-id>
        <award-id>P30CA023108</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="12"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Cancer is the second leading cause of death in the United States, following heart disease (<xref rid="B1" ref-type="bibr">1</xref>). One thousand six hundred seventy deaths are projected to be caused by cancer per day in 2023, aggregating to an estimated 609 820 cancer deaths in the year (<xref rid="B1" ref-type="bibr">1</xref>). Cancer metastasis is the primary cause of cancer mortality, representing around 90% of cancer deaths (<xref rid="B2" ref-type="bibr">2</xref>). Metastatic cancer hallmarks a significantly worse prognosis with limited treatment options and a low response rate (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). Cancer metastasis happens when advanced tumor cells acquire the ability to detach from the primary tumor tissue, migrate through the blood and lymphatic vessels, invade a distal tissue site, and proliferate at the new site (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). Although primary tumor site for metastatic cancer can usually be recognized by clinical procedures like imaging, immunohistochemistry (IHC) tests and pathological analyses, cancer of unknown primary (CUP) persists for advanced cancer with high tumor cell heterogeneity, atypical morphological patterns, and absence of identifiable features (<xref rid="B4" ref-type="bibr">4</xref>). CUP is defined as metastatic cancer for which the primary anatomic origin cannot be identified. CUP accounts for 2–5% of all cancers and marks significantly worse clinical outcomes (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>). The median survival rate is less than one year for CUP patients (<xref rid="B5" ref-type="bibr">5</xref>). Therapeutic strategies today are highly dependent on the clinical, pathological, and molecular profiles of cancer (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>). CUP poses the challenge of proper and timely treatment for patients, resulting in unfavorable clinical outcomes. Although clinical tools, e.g. IHC, pathology test, are available for identifying CUP, only 25% of CUP can be diagnosed due to the limited sensitivity and specificity of the traditional methods (<xref rid="B9" ref-type="bibr">9</xref>). Additional tools to assist CUP identification could be clinically important.</p>
    <p>DNA methylation is an epigenetic modification that regulates gene expression and is essential to establishing and preserving cellular identity (<xref rid="B10" ref-type="bibr">10</xref>). In recent years, DNA methylation has been widely utilized as a biomarker for cell typing in blood and the tumor microenvironment (<xref rid="B11" ref-type="bibr">11–14</xref>). Furthermore, cell-free DNA methylation profiling is beginning to show promise for early detection and classification of cancer (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>). As a well-established biomarker for cell identity, DNA methylation holds promising value for distinguishing heterogeneous tumor subtypes, especially for CUP. Genome-wide DNA methylation arrays provide a standardized and cost-effective approach to measuring DNA methylation (<xref rid="B17" ref-type="bibr">17</xref>). The high-dimensional methylation data in combination with artificial intelligence (AI) technologies promises new opportunities to efficiently trace tumor tissue of origin that may have clinical significance, especially for metastasized cancer and CUP.</p>
    <p>The advance of AI in biomedical science enables translational technology from sophisticated computational tasks and high-dimensional data to potential clinical usage (<xref rid="B18" ref-type="bibr">18</xref>). AI-powered medicine provides streamlined analysis and efficient processing of complex clinical and biomedical data, especially in pathology and laboratory medicine (<xref rid="B19" ref-type="bibr">19</xref>). In the past decade, by virtue of the progress made in computational capacity and new technologies for genomic sequencing, publicly available biomedical data repertoires were established and structured to serve the scientific community with easily accessible data sets, e.g. The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and ArrayExpress. Combined with advances in AI, researchers have utilized the enormity of publicly available data to study genomic biology. Perhaps the most popular example of these technologies is the AI-powered protein folding prediction research (<xref rid="B20" ref-type="bibr">20</xref>). At the genomic level, studies are beginning to show the application of machine learning modeling to integrate multiomics information for disease diagnosis and prognostication, which is especially relevant for studying cancer biology (<xref rid="B21" ref-type="bibr">21–23</xref>).</p>
    <p>In recent years, researchers have demonstrated high performance of DNA methylation-based machine learning models tracing the tissue origin of tumor cells (<xref rid="B24" ref-type="bibr">24–26</xref>). However, previous works were limited by the number and variation of cancer types and validation data sets considered, especially for metastasized cancers and circulating cell-free DNA from cancer patients. Furthermore, previous models were devised based on tissue site instead of tumor type, generating potential problems of indistinguishable tumor subtypes from the same site, e.g. esophageal squamous cell carcinoma versus esophageal adenocarcinoma. Although there is some work to illustrate the utility and replicability of the DNA methylation-based machine learning models on tracing tissue of origin for cancers, these works lacked tumor-type specificity and were not made readily accessible and user-friendly to the general scientific community. A previous study used a hierarchical modeling approach to address the challenge of deconvolving cell types that are of same lineage in the tumor microenvironment (<xref rid="B14" ref-type="bibr">14</xref>). Similarly, to address the limitations of existing methods and enhance the accuracy, utility and accessibility of tumor tracing, we developed a novel DNA methylation-based algorithm that employs a tumor-type-specific hierarchical model and broadens the number of solid tumor types that are traced. Our method, called Hierarchical Tumor Artificial Intelligence Classifier (HiTAIC), uses multilayer perceptron models in combination with the discriminatory CpGs specific to tumor type in each layer in the hierarchy, to trace tumor tissue of origin and subtypes in 27 primary and metastasized cancers. HiTAIC’s ability to trace tumor tissue of origin with high resolution promises valuable application to clinical CUP identification. HiTAIC is publicly accessible on a user-friendly web page <ext-link xlink:href="https://sites.dartmouth.edu/salaslabhitaic/" ext-link-type="uri">https://sites.dartmouth.edu/salaslabhitaic/</ext-link>.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Discovery dataset and quality control</title>
      <p>The initial discovery data sets included DNA methylation microarray data from 7932 samples across 30 cancer types with tagged known primary from TCGA, which is a publicly available cancer data repertoire. 194 leukemia samples were removed as we target only solid tumors. Ninety-nine ovarian tumor samples were added to the discovery data set from GEO data set GSE133556 due to limited ovarian tumor sample size on TCGA. 102 samples were excluded from the discovery data set because of the ambiguity of the tumor subtypes. The ambiguous tumors are rare tumor subtypes that do not fall into any category of the HiTAIC hierarchy. Supplementary Table S1 summarized the discovery data set based on cancer site, tumor subtype, and exclusion criteria. In total, 7735 tumor samples from 27 cancer types were included in the discovery data set (Table <xref rid="tbl1" ref-type="table">1</xref>). The discovery data set was then randomly split into 80% training and 20% testing for model training and testing. In the methylation data quality control process, we retained CpGs that measured on both Illumina HumanMethylation450k and HumanMethylationEPIC platforms to accommodate cross-platform applications. The <italic toggle="yes">SeSAMe</italic> (version 1.8.2) pipeline from Bioconductor was used to preprocess the data, including data normalization and quality control (<xref rid="B27" ref-type="bibr">27</xref>). Cross-reactive probes, SNP-related probes, sex chromosome probes, non-CpG probes and low-quality probes (pOOBHA &gt; 0.05) were masked in the analysis. 384640 CpGs were retained after this process.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Baseline characteristics of the discovery data set</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Cancer type</th>
              <th rowspan="1" colspan="1">Location</th>
              <th rowspan="1" colspan="1">
                <italic toggle="yes">N</italic>
              </th>
              <th rowspan="1" colspan="1">Mean age (SD)</th>
              <th rowspan="1" colspan="1">Male <italic toggle="yes">N</italic> (%)</th>
              <th rowspan="1" colspan="1">Data source</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Adrenocortical adenocarcinoma</td>
              <td rowspan="1" colspan="1">Adrenal gland</td>
              <td rowspan="1" colspan="1">80</td>
              <td rowspan="1" colspan="1">47 (15.9)</td>
              <td rowspan="1" colspan="1">31 (38.8)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Bladder adenocarcinoma</td>
              <td rowspan="1" colspan="1">Bladder</td>
              <td rowspan="1" colspan="1">410</td>
              <td rowspan="1" colspan="1">69 (10.6)</td>
              <td rowspan="1" colspan="1">303 (73.9)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast adenocarcinoma</td>
              <td rowspan="1" colspan="1">Breast</td>
              <td rowspan="1" colspan="1">761</td>
              <td rowspan="1" colspan="1">59 (13.2)</td>
              <td rowspan="1" colspan="1">9 (1.2)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cervical adenocarcinoma</td>
              <td rowspan="1" colspan="1">Cervix</td>
              <td rowspan="1" colspan="1">48</td>
              <td rowspan="1" colspan="1">46 (12.3)</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cervical squamous cell carcinoma</td>
              <td rowspan="1" colspan="1">Cervix</td>
              <td rowspan="1" colspan="1">259</td>
              <td rowspan="1" colspan="1">49 (14.0)</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Colorectal adenocarcinoma</td>
              <td rowspan="1" colspan="1">Colon and rectum</td>
              <td rowspan="1" colspan="1">379</td>
              <td rowspan="1" colspan="1">64 (12.9)</td>
              <td rowspan="1" colspan="1">202 (52.3)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glioma</td>
              <td rowspan="1" colspan="1">Brain</td>
              <td rowspan="1" colspan="1">138</td>
              <td rowspan="1" colspan="1">60 (12.8)</td>
              <td rowspan="1" colspan="1">80 (58.0)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kidney chromophobe adenocarcinoma</td>
              <td rowspan="1" colspan="1">Kidney</td>
              <td rowspan="1" colspan="1">66</td>
              <td rowspan="1" colspan="1">52 (14.3)</td>
              <td rowspan="1" colspan="1">39 (59.1)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kidney renal clear cell adenocarcinoma</td>
              <td rowspan="1" colspan="1">Kidney</td>
              <td rowspan="1" colspan="1">319</td>
              <td rowspan="1" colspan="1">61 (11.8)</td>
              <td rowspan="1" colspan="1">205 (64.3)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Kidney renal papillary cell adenocarcinoma</td>
              <td rowspan="1" colspan="1">Kidney</td>
              <td rowspan="1" colspan="1">275</td>
              <td rowspan="1" colspan="1">62 (12.1)</td>
              <td rowspan="1" colspan="1">202 (73.5)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Liver hepatocellular adenocarcinoma</td>
              <td rowspan="1" colspan="1">Liver</td>
              <td rowspan="1" colspan="1">377</td>
              <td rowspan="1" colspan="1">59 (13.5)</td>
              <td rowspan="1" colspan="1">255 (67.6)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung adenocarcinoma</td>
              <td rowspan="1" colspan="1">Lung</td>
              <td rowspan="1" colspan="1">458</td>
              <td rowspan="1" colspan="1">65 (10.2)</td>
              <td rowspan="1" colspan="1">214 (46.7)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung squamous cell carcinoma</td>
              <td rowspan="1" colspan="1">Lung</td>
              <td rowspan="1" colspan="1">370</td>
              <td rowspan="1" colspan="1">68 (8.7)</td>
              <td rowspan="1" colspan="1">274 (74.1)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic adenocarcinoma</td>
              <td rowspan="1" colspan="1">Pancreas</td>
              <td rowspan="1" colspan="1">175</td>
              <td rowspan="1" colspan="1">66 (11.0)</td>
              <td rowspan="1" colspan="1">98 (56.0)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate adenocarcinoma</td>
              <td rowspan="1" colspan="1">Prostate</td>
              <td rowspan="1" colspan="1">498</td>
              <td rowspan="1" colspan="1">61 (6.8)</td>
              <td rowspan="1" colspan="1">498 (100.0)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophageal and head and neck squamous cell carcinoma</td>
              <td rowspan="1" colspan="1">Esophagus and head and neck</td>
              <td rowspan="1" colspan="1">624</td>
              <td rowspan="1" colspan="1">61 (11.7)</td>
              <td rowspan="1" colspan="1">467 (75.8)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cutaneous melanoma</td>
              <td rowspan="1" colspan="1">Skin</td>
              <td rowspan="1" colspan="1">104</td>
              <td rowspan="1" colspan="1">65 (13.9)</td>
              <td rowspan="1" colspan="1">62 (59.6)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Uveal melanoma</td>
              <td rowspan="1" colspan="1">Eye</td>
              <td rowspan="1" colspan="1">80</td>
              <td rowspan="1" colspan="1">62 (14.0)</td>
              <td rowspan="1" colspan="1">45 (56.2)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophageal and stomach adenocarcinoma</td>
              <td rowspan="1" colspan="1">Esophagus and stomach</td>
              <td rowspan="1" colspan="1">484</td>
              <td rowspan="1" colspan="1">66 (10.9)</td>
              <td rowspan="1" colspan="1">336 (69.4)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thyroid adenocarcinoma</td>
              <td rowspan="1" colspan="1">Thyroid</td>
              <td rowspan="1" colspan="1">502</td>
              <td rowspan="1" colspan="1">47 (15.8)</td>
              <td rowspan="1" colspan="1">133 (26.5)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mesothelioma</td>
              <td rowspan="1" colspan="1">Pleura</td>
              <td rowspan="1" colspan="1">87</td>
              <td rowspan="1" colspan="1">64 (9.8)</td>
              <td rowspan="1" colspan="1">71 (81.6)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pheochromocytoma and Paraganglioma</td>
              <td rowspan="1" colspan="1">Adrenal gland</td>
              <td rowspan="1" colspan="1">179</td>
              <td rowspan="1" colspan="1">48 (15.1)</td>
              <td rowspan="1" colspan="1">78 (43.6)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Sarcoma</td>
              <td rowspan="1" colspan="1">Soft tissues</td>
              <td rowspan="1" colspan="1">249</td>
              <td rowspan="1" colspan="1">61 (14.7)</td>
              <td rowspan="1" colspan="1">113 (45.4)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Testicular germ cell tumor</td>
              <td rowspan="1" colspan="1">Testis</td>
              <td rowspan="1" colspan="1">150</td>
              <td rowspan="1" colspan="1">32 (9.3)</td>
              <td rowspan="1" colspan="1">150 (100)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Ovarian adenocarcinoma</td>
              <td rowspan="1" colspan="1">Ovary</td>
              <td rowspan="1" colspan="1">109</td>
              <td rowspan="1" colspan="1">49 (13.5)*</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">TCGA, GSE133556</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thymoma</td>
              <td rowspan="1" colspan="1">Thymus</td>
              <td rowspan="1" colspan="1">124</td>
              <td rowspan="1" colspan="1">59 (13.0)</td>
              <td rowspan="1" colspan="1">64 (51.6)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Endometrial adenocarcinoma</td>
              <td rowspan="1" colspan="1">Uterus</td>
              <td rowspan="1" colspan="1">430</td>
              <td rowspan="1" colspan="1">65 (11.2)</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">TCGA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Total</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">7735</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <label>*</label>
            <p>Horvath methylation age inferred using the <italic toggle="yes">wateRmelon</italic> package in R for GSE133556.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="SEC2-2">
      <title>Tumor classifier hierarchy and tumor type specific CpG identification</title>
      <p>The tumor classifier hierarchy was established based on cancer pathophysiological differences and tissue location by tumor type. Two layers with four categories were established for 27 cancer types in the hierarchy (Figure <xref rid="F1" ref-type="fig">1</xref>). Layer 1 contains nine major tumor types. Layer 2A contains 16 types of adenocarcinoma. Layer 2B includes three types of squamous cell carcinoma. Layer 2C includes two types of melanoma. The sample labels were generated by examining the primary diagnosis and cancer-type information from TCGA following the HiTAIC hierarchy. Sample labels can be found on FigShare (DOI: 10.6084/m9.figshare.22179089). To reduce the high-dimensionality of the DNA methylation data with 384 640 CpGs, we performed epigenome-wide association study (EWAS) to identity differentially methylated CpGs across the cancer types in each category of the hierarchy as input for machine-learning model training using the whole discovery dataset to maximize the power. We applied the <italic toggle="yes">Meffil</italic> (version 1.1.1) package in R (<xref rid="B28" ref-type="bibr">28</xref>), which used <italic toggle="yes">limma</italic> linear regression with empirical Bayes adjustment statistics to reduce methylation profiles to top 100 cell-type-specific hyper- and hypo-methylated CpGs per cancer type. Thus, four libraries of cancer-type discriminatory CpGs were developed. T-distributed stochastic neighbor embedding (T-SNE) was used to visualize the separation of cancers by methylation status from the <italic toggle="yes">Meffil</italic> selected CpGs in the libraries. R version 4.2.0 was used in this study.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>HiTAIC tumor classifier hierarchy with two layers for twenty-seven cancer types (created with BioRender.com).</p>
        </caption>
        <graphic xlink:href="zcad017fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC2-3">
      <title>Machine learning model development, validation and application</title>
      <p>All data mining and machine learning model building were operated in Jupyter Notebook Python 3 with the <italic toggle="yes">scikit-learn 1.1.1</italic> package (<xref rid="B29" ref-type="bibr">29</xref>). To select the best model, four different types of multi-class machine learning models were tested on the adenocarcinoma, squamous cell carcinoma, glioblastoma, and melanoma samples splitting to 80% training and 20% testing randomly. The support vector machine (SVM) model was established using the <italic toggle="yes">sklearn.svm.SVC</italic> function with gamma set as ‘auto’. The random forest classifier (RFC) was built using the <italic toggle="yes">sklearn.ensemble.RandomForestClassifier</italic> function with the number of trees set as 500. The Gaussian naïve Bayes (GNB) model was established using the <italic toggle="yes">sklearn.naive_bayes.GaussianNB</italic> function. Finally, the multilayer perceptron (MLP) model was built using the <italic toggle="yes">sklearn.neural_network.MLPClassifier</italic> function with the max number of iterations set at 300. The performances of the models were evaluated on the test data set using the <italic toggle="yes">sklearn.metrics.confusion_matrix</italic> and <italic toggle="yes">sklearn.metrics.classification_report</italic> functions, which include stratified and overall precision, recall and <italic toggle="yes">F</italic>1-score. Among four machine learning models applied, the MLP performed the best in the test data set (Supplementary Table S2). Thus, MLP model was selected as the final model for cancer classification. In each layer of the hierarchy, an MLP model was trained using the selected cancer type discriminatory CpGs. In total, four MLPs were developed for the hierarchy. HiTAIC was established based on the four hierarchical MLP models. Next, hyperparameter tuning was conducted to select the best set of hyperparameters for the MLP model in each layer of the hierarchy. The hidden layer parameter iterated through [100], [200], [500], [1000], [1000, 500], [1000, 200], [1000, 100], [500, 200], [500, 100], [200, 100], [1000, 500, 200], [1000, 500, 100], [500, 200, 100]. The optimizer iterated through ‘sgd’ and ‘adam’. The learning rate iterated through 0.0001, 0.0005, 0.001, 0.002, 0.005, 0.01. To ensure that the MLP model is generalizable and the performance of the model is consistency across the discovery data set, we established 5-fold cross-validation, which split the data into 80% training and 20% testing 5 times for model evaluation, in each layer of the hierarchy. For external validation, we identified 1175 samples with DNA methylation data on 24 cancer subtypes from 21 publicly available data sets on GEO and ArrayExpress (<xref rid="B30" ref-type="bibr">30–41</xref>) (Supplementary Table S3). To further validate HiTAIC on samples with a low tumor purity, we applied HiTAIC to TCGA adenocarcinoma samples with a tumor purity &lt;30% based on HITIMED DNA methylation tumor cell deconvolution (<xref rid="B14" ref-type="bibr">14</xref>). Although developed to trace tumor origin, we hypothesize that HiTAIC could also provide tissue of origin information on normal samples. As a result, we tested HiTAIC on normal tissues, including breast, lung, kidney, liver and colon, from TCGA with five samples per tissue type. We also tested HiTAIC on the 102 rare tumors we excluded for training. To demonstrate the application of the model in cancer metastasis, we identified 175 samples with DNA methylation data on five cancer types with six different metastatic locations from eight data sets on GEO and ArrayExpress (<xref rid="B42" ref-type="bibr">42–45</xref>) (Supplementary Table S4). We further identified 266 cfDNA samples with DNA methylation data from cancer patients in five types of cancer on GEO for application (<xref rid="B46" ref-type="bibr">46–50</xref>) (Supplementary Table S5). We applied the model to the external validation data sets computing stratified and overall precision, recall and <italic toggle="yes">F</italic>1-score to evaluate the performance. Next, we applied the model to the application data sets and used stratified and overall precision, recall, and F1-score to evaluate model performance in metastasized cancers and cfDNA from cancer patients.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Functional pathway and genomic context enrichment analyses</title>
      <p>To explore the potential biological pathways and functions related to the CpGs distinguishing cancers, we used the Genomic Regions Enrichment of Annotations Tool (GREAT) to perform enrichment analysis for cancer type specific CpGs in each layer in the hierarchy. GREAT uses Gene Ontology (GO) database, which includes biological process, cellular component, and molecular function categories. False discovery rate (FDR) was used to select and rank the significantly enriched GO terms (FDR &lt; 0.05). Next, genomic context enrichment analyses were conducted to investigate whether the cancer type specific CpGs are enriched in certain genomic locations. The relation of probes to CpG islands and enhancers was identified from the <italic toggle="yes">HumanMethylation450K</italic> annotation file. To define the genomic regions as promoters, introns, exons, or intergenic for each probe, the <italic toggle="yes">annotateWithGeneParts</italic> function from the R-package <italic toggle="yes">genomation</italic> and the <italic toggle="yes">UCSC_hg19_refGene</italic> file were used to map the regions to all CpG loci on the Illumina <italic toggle="yes">HumanMethylation450K</italic> array. If a probe mapped to more than a single genomic region, the probe was assigned preferentially with the order: promoters, exons, introns, and intergenic. Fisher's exact tests were conducted to calculate odds ratios (ORs), <italic toggle="yes">P</italic>-values and 95% confidence intervals for genomic context enrichment analysis. For both functional pathway and genomic context enrichment analyses, cancer discerning CpGs in each layer were tested over the background CpGs used (<italic toggle="yes">n</italic> = 384 640) for EWAS.</p>
    </sec>
    <sec id="SEC2-5">
      <title>HiTAIC web-based application development</title>
      <p>We used Python Dash and Heroku to develop a user-friendly web-based HiTAIC tool. Python Dash is a framework developed by Plotly, which is based on Python and used for building and deploying data apps with customized interface. Heroku, which is a cloud platform, was next employed to host and deploy the HITAIC web application. The HiTAIC web application contains two major parts. The first part is user guide. Users should follow the instructions to finish the prediction process. An exemplary input data csv file was available for demonstration. The second part includes data upload, model running, and output download. After constructing the input data as instructed, users can either click the data upload box to choose the file or drag the file to the box from the local end to upload the input data. Then the algorithm will automatically compute the output and show up on the right side of the panel. Users can also download the output result as a csv file by clicking the export box.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>RESULTS</title>
    <p>The pipeline of this study is shown in Figure <xref rid="F2" ref-type="fig">2</xref>. In total, four libraries of cancer type discriminatory CpGs were developed for the hierarchy. In Layer 1, 1641 CpGs were identified to discern nine major cancer types. In Layer 2A, 3225 CpGs were identified to distinguish 18 adenocarcinoma cancer types. In Layer 2B, 767 CpGs were identified to discriminate four squamous cell carcinoma cancer types. In Layer 2C, 200 CpGs were identified to discern two types of melanoma. The heatmaps in Figure <xref rid="F3" ref-type="fig">3</xref> demonstrated discriminative methylation status for the cancer type specific CpGs in the libraries. The libraries are relatively unique to each other as 0 overlapped CpGs were identified across the four libraries, one CpG appeared in three out of four libraries, and 80 CpGs in total overlapped in two out of four libraries (Supplementary Figure S1)</p>
    <fig position="float" id="F2">
      <label>Figure 2.</label>
      <caption>
        <p>Flowchart of HiTAIC model building, validation and application.</p>
      </caption>
      <graphic xlink:href="zcad017fig2" position="float"/>
    </fig>
    <fig position="float" id="F3">
      <label>Figure 3.</label>
      <caption>
        <p>DNA methylation states of cancer discriminating CpGs for Panel <bold>A</bold>. Layer 1 major cancer types; Panel <bold>B</bold>. Layer 2A adenocarcinoma subtypes; Panel <bold>C</bold>. Layer 2B squamous cell carcinoma subtypes; Panel <bold>D</bold>. Layer 2C melanoma subtypes.</p>
      </caption>
      <graphic xlink:href="zcad017fig3" position="float"/>
    </fig>
    <p>T-SNE clustering showed separation of clusters by cancer type using the cancer type discriminatory CpGs. However, certain cancer types did not show clear separation. Esophageal carcinoma was split into clusters with head and neck squamous cell carcinoma and stomach adenocarcinoma. Colon and rectum adenocarcinoma samples were indistinguishable in T-SNE (Supplementary Figure S2A). The two clusters of esophageal carcinoma can be separated by tumor subtypes, i.e. squamous cell carcinoma versus adenocarcinoma. Esophageal squamous cell carcinoma was clustered with head and neck squamous cell carcinoma (Supplementary Figure S2B) while esophageal adenocarcinoma was clustered with stomach adenocarcinoma (Supplementary Figure S2C). To avoid ambiguity and ensure the sensitivity of the model, we collapsed colon adenocarcinoma and rectal adenocarcinoma into colorectal adenocarcinoma in the adenocarcinoma layer, esophageal and head and neck squamous cell carcinoma into one group in the squamous cell carcinoma layer, and esophageal and stomach adenocarcinoma into one group in the adenocarcinoma layer in the hierarchy for MLP model training. Indicating differential methylation status by cancer types and feasibility for machine learning model training the T-SNE clustering showed clear separation of cancer types by using the cancer type discriminatory CpGs following the hierarchical cancer classification regime with minimal outliers. (Supplementary Figure S3).</p>
    <p>Next, HiTAIC was trained using the MLP models and cancer type discriminatory CpGs using the training data set following the hierarchical structure. HiTAIC integrated four MLP models for tracing tumor tissue of origin. With the 156 sets of hyperparameters examined, the accuracy ranged from 96–98%, 82–98%, 87–99% and 100% for Layer 1 (Supplementary Table S6), Layer 2A (Supplementary Table S7), Layer 2B (Supplementary Table S8) and Layer 2C (Supplementary Table S9) respectively. As a result, we selected 1 hidden layer with 100 nodes, ‘adam’ optimizer, and 0.001 learning rate as the hyperparameters for the final model. The architecture of the HiTAIC model is shown in Supplementary Table S10. Specifically in the testing data set, in Layer 1, HiTAIC performed with 98% accuracy and 98% weighted average F1-score (Table <xref rid="tbl2" ref-type="table">2</xref>). In Layer 2A with adenocarcinoma, HiTAIC performed with 98% accuracy and 98% weighted average F1-score (Table <xref rid="tbl3" ref-type="table">3</xref>). In Layer 2B with squamous cell carcinoma, HiTAIC performed with 99% accuracy and 99% weighted average F1-score (Table <xref rid="tbl4" ref-type="table">4</xref>). In Layer 2C with melanoma, HiTAIC performed with 100% accuracy and 100% weighted average <italic toggle="yes">F</italic>1-score (Table <xref rid="tbl5" ref-type="table">5</xref>). For 5-fold cross-validation, the model performed consistently well in every layer of the hierarchy. In Layer 1, the accuracy and weighted average <italic toggle="yes">F</italic>1-score are all 98% (Supplementary Table S11). In Layer 2A, the accuracy and weighted average F1-score ranged from 98% to 99% (Supplementary Table S12). In Layer 2B, the accuracy and weighted average <italic toggle="yes">F</italic>1-score ranged from 96% to 99% (Supplementary Table S13). In Layer 2C, the accuracy and weighted average <italic toggle="yes">F</italic>1-score ranged from 97% to 100% (Supplementary Table S14). HiTIMED identified 101 TCGA adenocarcinoma samples with a tumor purity below 30% (<xref rid="B14" ref-type="bibr">14</xref>) (Supplementary Table S15). HiTAIC achieved 97% accuracy and 98% weighted average F1-score on those samples (Supplementary Table S16). When applied to normal tissues, HiTAIC classified them into their corresponding tumor types, i.e. normal breast as breast adenocarcinoma, normal lung as lung adenocarcinoma, normal kidney as kidney adenocarcinoma, normal liver as liver adenocarcinoma and normal colon as colorectal adenocarcinoma (Supplementary Table S17). When applied to the 102 rare tumors that excluded for model training, HiTAIC achieved 81% accuracy to trace tissue of origin (Supplementary Table S18). Although the accuracy is lower relative to its performance on more common tumor subtypes, HiTAIC provides useful information that might be clinically useful for the rare tumors. For example, two bladder squamous cell carcinoma samples were accurately classified as squamous cell carcinoma in the first layer of HiTAIC classification despite that HiTAIC does not have a bladder squamous cell carcinoma category.</p>
    <table-wrap position="float" id="tbl2">
      <label>Table 2.</label>
      <caption>
        <p>HiTAIC performance on the test data set for Layer 1 cancer types</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Layer 1</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1"><italic toggle="yes">F</italic>1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">1075</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Glioma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">27</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Melanoma</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td rowspan="1" colspan="1">37</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Mesothelioma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td rowspan="1" colspan="1">17</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Pheochromocytoma and paraganglioma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">36</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Sarcoma</td>
            <td align="center" rowspan="1" colspan="1">0.92</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td rowspan="1" colspan="1">50</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Squamous cell carcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td rowspan="1" colspan="1">251</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Testicular germ cell tumor</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">30</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Thymoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">25</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">1548</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">1548</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Weighted average</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">1548</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tbl3">
      <label>Table 3.</label>
      <caption>
        <p>HiTAIC performance on the test data set for Layer 2A (adenocarcinoma) cancer subtypes</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Layer 2A (adenocarcinoma)</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1"><italic toggle="yes">F</italic>1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Adrenocortical</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">16</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Bladder</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">82</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Breast</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">152</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Cervical</td>
            <td align="center" rowspan="1" colspan="1">0.88</td>
            <td align="center" rowspan="1" colspan="1">0.7</td>
            <td align="center" rowspan="1" colspan="1">0.78</td>
            <td rowspan="1" colspan="1">10</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Colorectal</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td rowspan="1" colspan="1">76</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endometrial</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">86</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Kidney chromophobe</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td rowspan="1" colspan="1">13</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Kidney clear cell</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.92</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td rowspan="1" colspan="1">64</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Kidney papillary cell</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td rowspan="1" colspan="1">55</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Liver hepatocellular</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">75</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Esophageal and stomach</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">97</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Lung</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">92</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Ovarian</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">22</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Pancreatic</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td rowspan="1" colspan="1">35</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Prostate</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">100</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Thyroid</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">100</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">1075</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td rowspan="1" colspan="1">1075</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Weighted average</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">1075</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tbl4">
      <label>Table 4.</label>
      <caption>
        <p>HiTAIC performance on the test data set for Layer 2B (squamous cell carcinoma) cancer subtypes</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Layer 2B (squamous cell carcinoma)</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1"><italic toggle="yes">F</italic>1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Cervical</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">52</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Esophageal and head and neck</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">125</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Lung</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">74</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">251</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">251</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Weighted average</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">251</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tbl5">
      <label>Table 5.</label>
      <caption>
        <p>HiTAIC performance on the test data set for Layer 2C (melanoma) cancer subtypes</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Layer 2C (melanoma)</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1">F1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Eye uveal</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">16</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Skin cutaneous</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">21</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">37</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">37</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Weighted average</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">37</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <p>For external validation, we observed 93% accuracy and 93% weighted average F1-score across 25 cancer types (Table <xref rid="tbl6" ref-type="table">6</xref>). Specifically, all cancer types showed a <italic toggle="yes">F</italic>1-score over 80% except for endometrial adenocarcinoma (F1-score 51%) and ovarian adenocarcinoma (F1-score 77%). Among 65 ovarian adenocarcinomas in the validation data set, 16 were misclassified. All of them were misclassified as endometrial adenocarcinoma, resulting in a compromised <italic toggle="yes">F</italic>1-score for endometrial adenocarcinoma and ovarian adenocarcinoma. Although the <italic toggle="yes">F</italic>1-scores were relatively low in endometrial adenocarcinoma and ovarian adenocarcinoma, the misclassification were contained within the gynecologic cancer types, which still provides valuable information for tracing tumor tissue of origin.</p>
    <table-wrap position="float" id="tbl6">
      <label>Table 6.</label>
      <caption>
        <p>HiTAIC performance on the external validation data set</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Cancer type</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1"><italic toggle="yes">F</italic>1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Adrenocortical adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.72</td>
            <td align="center" rowspan="1" colspan="1">0.84</td>
            <td rowspan="1" colspan="1">18</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Bladder adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.78</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.88</td>
            <td rowspan="1" colspan="1">25</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Breast adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">188</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Cervical adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Cervical squamous cell carcinoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.67</td>
            <td align="center" rowspan="1" colspan="1">0.8</td>
            <td rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Colorectal adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.89</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td rowspan="1" colspan="1">54</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Endometrial adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.35</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.51</td>
            <td rowspan="1" colspan="1">9</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Eye uveal melanoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.78</td>
            <td align="center" rowspan="1" colspan="1">0.88</td>
            <td rowspan="1" colspan="1">23</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Glioma</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">70</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Esophageal and head and neck squamous cell carcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.73</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.84</td>
            <td rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Kidney clear cell carcinoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">17</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Liver hepatocellular carcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">66</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Esophageal and stomach adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.92</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td rowspan="1" colspan="1">12</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Lung adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td rowspan="1" colspan="1">47</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Lung squamous cell carcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.86</td>
            <td align="center" rowspan="1" colspan="1">0.92</td>
            <td rowspan="1" colspan="1">57</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Mesothelioma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.85</td>
            <td align="center" rowspan="1" colspan="1">0.92</td>
            <td rowspan="1" colspan="1">79</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Ovarian adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.79</td>
            <td align="center" rowspan="1" colspan="1">0.75</td>
            <td align="center" rowspan="1" colspan="1">0.77</td>
            <td rowspan="1" colspan="1">65</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Pancreatic adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.8</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.89</td>
            <td rowspan="1" colspan="1">12</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Pheochromocytoma and Paraganglioma</td>
            <td align="center" rowspan="1" colspan="1">0.85</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.92</td>
            <td rowspan="1" colspan="1">22</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Prostate adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">0.89</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td rowspan="1" colspan="1">25</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Sarcoma</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.91</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td rowspan="1" colspan="1">158</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Skin cutaneous melanoma</td>
            <td align="center" rowspan="1" colspan="1">0.9</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td rowspan="1" colspan="1">46</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Testicular germ cell tumor</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td rowspan="1" colspan="1">130</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Thymoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.82</td>
            <td align="center" rowspan="1" colspan="1">0.9</td>
            <td rowspan="1" colspan="1">11</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Thyroid adenocarcinoma</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">27</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td rowspan="1" colspan="1">1175</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td align="center" rowspan="1" colspan="1">0.91</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td align="center" rowspan="1" colspan="1">0.91</td>
            <td rowspan="1" colspan="1">1175</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">weighted average</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td rowspan="1" colspan="1">1175</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <p>In metastasized cancer, HiTAIC demonstrated 96% accuracy and 98% weighted average <italic toggle="yes">F</italic>1-score across five cancer types with six different metastatic locations (colon to liver, colon to lung, lung to brain, prostate to bone, prostate to liver, prostate to lymph node, breast to lymph node, testis to lung, testis to lymph node) (Table <xref rid="tbl7" ref-type="table">7</xref>). In cfDNA from cancer patients, the model has low performance with 15% accuracy and a weighted <italic toggle="yes">F</italic>1-score of 24% (Table <xref rid="tbl8" ref-type="table">8</xref>). Taken together, HiTAIC traces tumor tissue of origin and cancer subtype with a high accuracy in primary and metastasized cancer but not in cfDNA from cancer patients.</p>
    <table-wrap position="float" id="tbl7">
      <label>Table 7.</label>
      <caption>
        <p>HiTAIC performance on metastasized tumors</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Original cancer type</th>
            <th rowspan="1" colspan="1">Metastasized location</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1"><italic toggle="yes">F</italic>1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Breast</td>
            <td rowspan="1" colspan="1">Lymph node</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">44</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Colon</td>
            <td rowspan="1" colspan="1">Liver, Lung</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.93</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td rowspan="1" colspan="1">29</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Lung</td>
            <td rowspan="1" colspan="1">Brain</td>
            <td align="center" rowspan="1" colspan="1">0.94</td>
            <td align="center" rowspan="1" colspan="1">0.85</td>
            <td align="center" rowspan="1" colspan="1">0.89</td>
            <td rowspan="1" colspan="1">20</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Prostate</td>
            <td rowspan="1" colspan="1">Bone, Liver, Lymph node</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td rowspan="1" colspan="1">76</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Testicular germ cell tumor</td>
            <td rowspan="1" colspan="1">Lung, Lymph node</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">6</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td rowspan="1" colspan="1">175</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.95</td>
            <td align="center" rowspan="1" colspan="1">0.97</td>
            <td rowspan="1" colspan="1">175</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Weighted average</td>
            <td rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.99</td>
            <td align="center" rowspan="1" colspan="1">0.96</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td rowspan="1" colspan="1">175</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tbl8">
      <label>Table 8.</label>
      <caption>
        <p>HiTAIC performance on cell-free DNA from cancer patients</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Cancer type</th>
            <th rowspan="1" colspan="1">Precision</th>
            <th rowspan="1" colspan="1">Recall</th>
            <th rowspan="1" colspan="1"><italic toggle="yes">F</italic>1-score</th>
            <th rowspan="1" colspan="1">Sample size</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Breast cancer</td>
            <td align="center" rowspan="1" colspan="1">0.33</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.5</td>
            <td rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Colorectal cancer</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.75</td>
            <td align="center" rowspan="1" colspan="1">0.86</td>
            <td rowspan="1" colspan="1">4</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Liver cancer</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.09</td>
            <td align="center" rowspan="1" colspan="1">0.17</td>
            <td rowspan="1" colspan="1">22</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Lung cancer</td>
            <td align="center" rowspan="1" colspan="1">0</td>
            <td align="center" rowspan="1" colspan="1">0</td>
            <td align="center" rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">4</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Prostate cancer</td>
            <td align="center" rowspan="1" colspan="1">1</td>
            <td align="center" rowspan="1" colspan="1">0.13</td>
            <td align="center" rowspan="1" colspan="1">0.23</td>
            <td rowspan="1" colspan="1">233</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Accuracy</td>
            <td align="center" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1"/>
            <td align="center" rowspan="1" colspan="1">0.15</td>
            <td rowspan="1" colspan="1">266</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Macro average</td>
            <td align="center" rowspan="1" colspan="1">0.67</td>
            <td align="center" rowspan="1" colspan="1">0.39</td>
            <td align="center" rowspan="1" colspan="1">0.36</td>
            <td rowspan="1" colspan="1">266</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Weighted average</td>
            <td align="center" rowspan="1" colspan="1">0.98</td>
            <td align="center" rowspan="1" colspan="1">0.15</td>
            <td align="center" rowspan="1" colspan="1">0.24</td>
            <td rowspan="1" colspan="1">266</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <p>To investigate the biological pathways enriched for the cancer-discerning CpGs, we conducted pathway enrichment analysis using GREAT. We identified significantly enriched GO biological processes, cellular components, and molecular functions for each layer in the hierarchy. In Layer 1, the top 10 enriched biological pathways involve substantially cell differentiation and morphogenesis (Figure <xref rid="F4" ref-type="fig">4A</xref>). In Layer 2A, which is designed for adenocarcinoma classification, the top 10 enriched biological pathways include majorly inositol phosphate metabolism (Figure <xref rid="F4" ref-type="fig">4B</xref>). In Layer 2B, which is designed for squamous cell carcinoma classification, the top 10 enriched biological pathways contain mostly lung cell differentiation and development (Figure <xref rid="F4" ref-type="fig">4C</xref>). In Layer 2C, which is designed for melanoma classification, the top 10 enriched biological pathways involve skeletal system development, regionalization process and embryonic morphogenesis (Figure <xref rid="F4" ref-type="fig">4D</xref>). Multiple genomic context enrichment analyses were conducted to investigate whether the cancer specific CpGs are enriched in certain genomic locations. The Layer 1 and Layer 2A CpGs were significantly enriched for open sea, exon, intron and enhancer regions (Supplementary Figure S4A, Supplementary Figure S4B). The Layer 2B CpGs were significantly over-represented in CpG island and promoter regions (Supplementary Figure S4C). The Layer 2C CpGs were significantly enriched for open sea, intron, and enhancer regions (Supplementary Figure S4D).</p>
    <fig position="float" id="F4">
      <label>Figure 4.</label>
      <caption>
        <p>GREAT Gene Ontology pathways enriched for CpGs discerning: Panel <bold>A:</bold> major cancer types; Panel <bold>B:</bold> adenocarcinoma subtypes; Panel <bold>C:</bold> squamous cell carcinoma subtypes; Panel <bold>D</bold>: melanoma subtypes.</p>
      </caption>
      <graphic xlink:href="zcad017fig4" position="float"/>
    </fig>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>DISCUSSION</title>
    <p>DNA methylation is well studied to show significant alteration in carcinogenesis, particularly hypermethylation in tumor suppressor genes and hypomethylation in oncogenes (<xref rid="B51" ref-type="bibr">51</xref>). Although methylation alteration is a generic phenomenon in cancer, the across-cancer-type heterogeneity of genetic and epigenetic landscape enables distinguishable methylation patterns by tumor type (<xref rid="B52" ref-type="bibr">52</xref>). Furthermore, DNA methylation retains tissue and cell identities as it marks cell fate determination, which we hypothesized would enable identification of tumor tissue of origin and tumor type (<xref rid="B10" ref-type="bibr">10</xref>). We developed and validated DNA methylation-based machine learning model, HiTAIC, to trace tissue of origin and tumor type in 27 primary tumor types. We also demonstrated its high performance in metastasized cancers.</p>
    <p>Previous research has demonstrated the application of machine learning models on genetic and epigenetic data to develop clinical biomarkers for disease diagnosis and prognosis, including cancer (<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B53" ref-type="bibr">53</xref>). DNA methylation-based machine learning models have demonstrated the capability to infer the location of unknown primary site from the site of metastasis (<xref rid="B24" ref-type="bibr">24–26</xref>). However, previous models heavily favored inference of tissue site instead of tumor type, generating potential problems of indistinguishable tumor subtypes from the same site. Tumor cells originating from the same organ could exhibit widely varying histology and pathogenesis. For example, we observed that esophageal carcinoma can be dichotomized into two clusters by DNA methylation profile, one with head and neck squamous cell carcinoma and the other with stomach adenocarcinoma. Thus, a single-layer classification of ‘esophagus cancer’ would conflate head and neck squamous cell carcinoma and stomach adenocarcinoma. To address the issue, we used a multilayer hierarchical approach with differential DNA patterns by tumor type to achieve high-resolution tumor tissue of origin and subtype tracing. Our previous publication using DNA methylation data with hierarchical modeling achieved high-resolution deconvolution of the tumor microenvironment (<xref rid="B14" ref-type="bibr">14</xref>). In HiTAIC, adenocarcinoma and squamous cell carcinoma were initially distinguished, eliminating the potential issue of confusing esophageal adenocarcinoma with esophageal squamous cell carcinoma. Furthermore, previous work has limited cancer types and validation data sets, especially for metastasized cancers and cell-free DNA from cancer patients. Noticeably, previous work did not provide a user-friendly and accessible tool for the generic scientific community. HiTAIC, on the other hand, included 27 cancer types from 23 tissue sites in the discovery data sets, validated using external data sets, and demonstrated utility in external metastasized cancers. For easy accessibility of the algorithm and accommodate users without coding experience, a web-based app is developed and now available through <ext-link xlink:href="https://sites.dartmouth.edu/salaslabhitaic/" ext-link-type="uri">https://sites.dartmouth.edu/salaslabhitaic/</ext-link>. Our effort emphasizes the computational biology research translatability from machine to the scientific and clinical community.</p>
    <p>Importantly, HiTAIC traces tissue of origin and tumor type in metastasized cancers with a high accuracy, providing insight into the identification of CUP. Previous research developed a methylation-based assay for tracing CUP, EPICUP, showed significantly better prognosis for CUP cases that were treated with site-specific therapy based on the assay compared to the CUP cases treated with empiric therapy, emphasizing the clinical significance of CUP diagnosis and directing the future of CUP diagnosis towards precision medicine (<xref rid="B9" ref-type="bibr">9</xref>). Although not yet clinically deployable as EPICUP, the hierarchical modeling approach employed by HiTAIC maximizes the power of detecting most differentially methylated CpGs in granular tumor subtypes and is a more research friendly bioinformatic tool that can serve the research community and facilitate research which involves inferring the primary tumor site of unknown origin.</p>
    <p>The predictability of the HiTAIC model is based on four libraries of CpGs discerning different layers of cancer subtypes. Interestingly, the four CpG libraries are almost completely distinct from each other with very low overlap. The biological pathways and genomic context enriched across the libraries are also diverse, indicating differential pathways involved in carcinogenesis and morphogenesis for different organ sites. In Layer 1, top enriched pathways are associated with cell differentiation, morphogenesis, and function. We posit that the distinguishable epigenetic regulation in cell differentiation resulted from the substantially distinctive cancer types and tumor sites in Layer 1. In Layer 2A, which is designed for adenocarcinoma classification, inositol phosphate metabolism related pathways were highly enriched. Inositol phosphate metabolic pathways are crucial for regulating cell migration, proliferation, apoptosis, and phosphatidylinositol-3-kinase (PI3K)/Akt signaling under normal physiological conditions. Studies have shown that dysregulation in inositol phosphate metabolism plays a key role in carcinogenesis. Tan et al. demonstrated gene variants in the inositol phosphate metabolism pathways are associated with risk of four types of cancer, including lung, esophageal, stomach, and kidney(<xref rid="B54" ref-type="bibr">54</xref>). Two studies showed the association between inositol phosphate metabolism and cancer aggressiveness in both human and mouse models (<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>). The biological implications of distinguishability for adenocarcinoma by differential epigenetic patterns regulating inositol phosphate metabolic pathways is intriguing and promises further investigation. Top pathways enriched for squamous cell carcinoma classification in Layer 2B involve lung cell differentiation, emphasizing tumor originating site specification to discern squamous cell carcinoma. To distinguish between cutaneous and uveal melanoma, top pathways were enriched for embryonic development. Differential biological pathways identified for distinguishing different cancer subtypes promote further investigation of differential epigenetic regulation in carcinogenesis and morphogenesis by tumor subtype and tumor originating site.</p>
    <p>While our study developed a solid pipeline and user-friendly algorithm, HiTAIC, for cancer tracing, we recognize some limitations. First, esophageal carcinoma cannot be discerned by its own category. The esophageal squamous cell carcinoma was collapsed into head and neck squamous cell carcinoma whereas the esophageal adenocarcinoma was collapsed into stomach adenocarcinoma. Previous studies revealed disparities in the classification of esophageal carcinoma with stomach adenocarcinoma and head and neck squamous cell carcinoma (<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>). Although esophageal cancer cannot be distinguished from stomach or head and neck cancer, HiTAIC still provides a general location of the tumor of interest, which is clinically important. While previous tools treated esophageal carcinoma as an individual cancer type, our study revealed dichotomized methylation patterns of esophageal carcinoma subtypes. HiTAIC addressed the issue by employing a hierarchical modeling approach. We believe this is critical to enhance the accuracy of the model to trace esophageal carcinoma subtypes. Second, for external validation, kidney papillary and chromophobe cancers were not included as no other resources were available for those tumors other than TCGA. However, in the test data set, HiTAIC demonstrated high accuracy in predicting those two kidney tumor subtypes. Third, due to the limited data source, the performance of HiTAIC in metastasized tumor and cell free DNA were evaluated only in five cancer types respectively. Future analyses are necessary on more metastasized cancer type and cell free DNA. Finally, HiTAIC does not work well in tracing cancer in cfDNA based on the data analyzed. As HiTAIC was developed based on differential DNA methylome in solid tumor tissues, it is not optimized to work in a noisy cfDNA environment mixed with blood DNA signals and low abundance of tumor DNA. Therefore, we emphasize the importance of developing environment-specific tools, e.g. in body fluids like peripheral blood serum, menstrual blood, human milk, cerebrospinal fluid, for tracing tumor DNA to correct for the background noise.</p>
    <p>HiTAIC provides a comprehensive tracing of major tumor sites and types. Future studies should focus on the development of tumor-specific subtype libraries to expand the classification hierarchy as molecular and anatomic subtypes of certain tumors have been showed to be differentially regulated by DNA methylation (<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>). Although HiTAIC can provide information on tissue of origin, we do not encourage the use of HiTAIC to non-tumor tissues as that deviates the purpose of HiTAIC. Future research on the development of DNA methylation-based normal tissue classifier is necessary.</p>
  </sec>
  <sec sec-type="conclusions" id="SEC5">
    <title>CONCLUSION</title>
    <p>We developed HiTAIC, a DNA methylation-based multilayer perceptron classifier, to trace tissue of origin and tumor type in primary and metastasized tumors. The capability of the model tracing the tumor origin and subtype with high resolution and accuracy promises potential clinical use in identifying cancer of unknown origin and thus strategizing treatment plan to achieve precision medicine. HiTAIC can be easily deployed in a web-based application, which transformed the computational sophistication to a more user-friendly tool for public.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC6">
    <title>DATA AVAILABILITY</title>
    <p>All data sets used in this study are publicly available on The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and ArrayExpress. The accession numbers are GSE133556, GSE77871, GSE75067, GSE169622, GSE193535, GSE123678, GSE67114, GSE54503, E-MTAB-10156, GSE74071, GSE52955, GSE140169, GSE164988, GSE121377, GSE156876, GSE164269, GSE167059, GSE43293, GSE65820, GSE74104, GSE94769, GSE93589, GSE53051, GSE77954, GSE116699, E-MTAB-8660, GSE174613, GSE116338, GSE58999, GSE156512, GSE122126, GSE129374, GSE108462, GSE119260, GSE157273. HiTAIC is publicly accessible on a user-friendly web page <ext-link xlink:href="https://sites.dartmouth.edu/salaslabhitaic/" ext-link-type="uri">https://sites.dartmouth.edu/salaslabhitaic/</ext-link>. Code and documents are shared on FigShare (DOI: 10.6084/m9.figshare.22179089).</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcad017_Supplemental_File</label>
      <media xlink:href="zcad017_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p><italic toggle="yes">Author contributions:</italic> Conceptualization, Z.Z., L.A.S., B.C.C., S.V.; Methodology, Z.Z., L.A.S., B.C.C., S.V., J.L.; Software, Z.Z., J.L., Y.L.; Validation, Z.Z.; Formal Analysis, Z.Z..; Investigation, Z.Z., L.A.S.; Resources, Z.Z.; Data Curation, Z.Z.; Writing – Original Draft Preparation, Z.Z., L.A.S.; Writing – Review &amp; Editing, Z.Z., L.A.S., B.C.C., S.V., J.L., Y.L.; Visualization, Z.Z., L.A.S., Y.L., J.L.; Supervision, L.A.S., B.C.C., J.L.; Project Administration, Z.Z., L.A.S.; Funding Acquisition, L.A.S., B.C.C.</p>
  </ack>
  <sec id="SEC7">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcad017#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC8">
    <title>FUNDING</title>
    <p>Department of Defense [W81XWH-20-1-0778]; National Institute of General Medical Sciences [P20GM104416/8299]; National Cancer Institute [R01CA253976, R01CA216265, R01CA275974, P30CA023108].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. HiTAIC has a pending patent application through Dartmouth College Technology Transfer Office with the invention disclosure number 2023–021. The inventors listed on the patent application are Ze Zhang, Lucas A Salas and Brock C Christensen. This tool is provided ‘as-is’ and is intended FOR RESEARCH USE ONLY, and it must not be used for any clinical purposes, including diagnosis or treatment of diseases. The authors are not responsible for the accuracy of analysis results.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname>  <given-names>R.L.</given-names></string-name>, <string-name><surname>Miller</surname>  <given-names>K.D.</given-names></string-name>, <string-name><surname>Fuchs</surname>  <given-names>H.E.</given-names></string-name>, <string-name><surname>Jemal</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Cancer statistics, 2022</article-title>. <source>CA Cancer J. Clin.</source>  <year>2022</year>; <volume>72</volume>:<fpage>7</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">35020204</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guan</surname>  <given-names>X.</given-names></string-name></person-group>  <article-title>Cancer metastases: challenges and opportunities</article-title>. <source>Acta Pharm. Sin. B</source>. <year>2015</year>; <volume>5</volume>:<fpage>402</fpage>–<lpage>418</lpage>.<pub-id pub-id-type="pmid">26579471</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fares</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Fares</surname>  <given-names>M.Y.</given-names></string-name>, <string-name><surname>Khachfe</surname>  <given-names>H.H.</given-names></string-name>, <string-name><surname>Salhab</surname>  <given-names>H.A.</given-names></string-name>, <string-name><surname>Fares</surname>  <given-names>Y.</given-names></string-name></person-group>  <article-title>Molecular principles of metastasis: a hallmark of cancer revisited</article-title>. <source>Signal Transduct. Target. Ther.</source>  <year>2020</year>; <volume>5</volume>:<fpage>28</fpage>.<pub-id pub-id-type="pmid">32296047</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kolling</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Ventre</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Geuna</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Milan</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Pisacane</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Boccaccio</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Sapino</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Montemurro</surname>  <given-names>F.</given-names></string-name></person-group>  <article-title>Metastatic cancer of unknown primary” or “primary Metastatic cancer”?</article-title>. <source>Front. Oncol.</source>  <year>2019</year>; <volume>9</volume>:<fpage>1546</fpage>.<pub-id pub-id-type="pmid">32010631</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qaseem</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Usman</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Jayaraj</surname>  <given-names>J.S.</given-names></string-name>, <string-name><surname>Janapala</surname>  <given-names>R.N.</given-names></string-name>, <string-name><surname>Kashif</surname>  <given-names>T.</given-names></string-name></person-group>  <article-title>Cancer of unknown primary: a review on clinical guidelines in the development and targeted management of patients with the unknown primary site</article-title>. <source>Cureus</source>. <year>2019</year>; <volume>11</volume>:<fpage>e5552</fpage>.<pub-id pub-id-type="pmid">31695975</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Massard</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Loriot</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Fizazi</surname>  <given-names>K.</given-names></string-name></person-group>  <article-title>Carcinomas of an unknown primary origin–diagnosis and treatment</article-title>. <source>Nat. Rev. Clin. Oncol.</source>  <year>2011</year>; <volume>8</volume>:<fpage>701</fpage>–<lpage>710</lpage>.<pub-id pub-id-type="pmid">22048624</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varadhachary</surname>  <given-names>G.R.</given-names></string-name>, <string-name><surname>Raber</surname>  <given-names>M.N.</given-names></string-name></person-group>  <article-title>Cancer of unknown primary site</article-title>. <source>N. Engl. J. Med.</source>  <year>2014</year>; <volume>371</volume>:<fpage>757</fpage>–<lpage>765</lpage>.<pub-id pub-id-type="pmid">25140961</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rassy</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Pavlidis</surname>  <given-names>N.</given-names></string-name></person-group>  <article-title>Progress in refining the clinical management of cancer of unknown primary in the molecular era</article-title>. <source>Nat. Rev. Clin. Oncol.</source>  <year>2020</year>; <volume>17</volume>:<fpage>541</fpage>–<lpage>554</lpage>.<pub-id pub-id-type="pmid">32350398</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Niazi</surname>  <given-names>M.K.K.</given-names></string-name>, <string-name><surname>Parwani</surname>  <given-names>A.V.</given-names></string-name>, <string-name><surname>Gurcan</surname>  <given-names>M.N.</given-names></string-name></person-group>  <article-title>Digital pathology and artificial intelligence</article-title>. <source>Lancet Oncol.</source>  <year>2019</year>; <volume>20</volume>:<fpage>e253</fpage>–<lpage>e261</lpage>.<pub-id pub-id-type="pmid">31044723</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bogdanovic</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Lister</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>DNA methylation and the preservation of cell identity</article-title>. <source>Curr. Opin. Genet. Dev.</source>  <year>2017</year>; <volume>46</volume>:<fpage>9</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">28651214</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salas</surname>  <given-names>L.A.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Koestler</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Butler</surname>  <given-names>R.A.</given-names></string-name>, <string-name><surname>Hansen</surname>  <given-names>H.M.</given-names></string-name>, <string-name><surname>Molinaro</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Wiencke</surname>  <given-names>J.K.</given-names></string-name>, <string-name><surname>Kelsey</surname>  <given-names>K.T.</given-names></string-name>, <string-name><surname>Christensen</surname>  <given-names>B.C.</given-names></string-name></person-group>  <article-title>Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling</article-title>. <source>Nat. Commun.</source>  <year>2022</year>; <volume>13</volume>:<fpage>761</fpage>.<pub-id pub-id-type="pmid">35140201</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arneson</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Yang</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>K.</given-names></string-name></person-group>  <article-title>MethylResolver-a method for deconvoluting bulk DNA methylation profiles into known and unknown cell contents</article-title>. <source>Commun. Biol.</source>  <year>2020</year>; <volume>3</volume>:<fpage>422</fpage>.<pub-id pub-id-type="pmid">32747663</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chakravarthy</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Furness</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Joshi</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Ghorani</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Ford</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Ward</surname>  <given-names>M.J.</given-names></string-name>, <string-name><surname>King</surname>  <given-names>E.V.</given-names></string-name>, <string-name><surname>Lechner</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Marafioti</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Quezada</surname>  <given-names>S.A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Pan-cancer deconvolution of tumour composition using DNA methylation</article-title>. <source>Nat. Commun.</source>  <year>2018</year>; <volume>9</volume>:<fpage>3220</fpage>.<pub-id pub-id-type="pmid">30104673</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Wiencke</surname>  <given-names>J.K.</given-names></string-name>, <string-name><surname>Kelsey</surname>  <given-names>K.T.</given-names></string-name>, <string-name><surname>Koestler</surname>  <given-names>D.C.</given-names></string-name>, <string-name><surname>Christensen</surname>  <given-names>B.C.</given-names></string-name>, <string-name><surname>Salas</surname>  <given-names>L.A.</given-names></string-name></person-group>  <article-title>HiTIMED: hierarchical tumor immune microenvironment epigenetic deconvolution for accurate cell type resolution in the tumor microenvironment using tumor-type-specific DNA methylation data</article-title>. <source>J. Transl. Med.</source>  <year>2022</year>; <volume>20</volume>:<fpage>516</fpage>.<pub-id pub-id-type="pmid">36348337</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Gole</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gore</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>He</surname>  <given-names>Q.</given-names></string-name>, <string-name><surname>Lu</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Min</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Yuan</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Yang</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Jiang</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>T.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Non-invasive early detection of cancer four years before conventional diagnosis using a blood test</article-title>. <source>Nat. Commun.</source>  <year>2020</year>; <volume>11</volume>:<fpage>3475</fpage>.<pub-id pub-id-type="pmid">32694610</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Zhou</surname>  <given-names>X.J.</given-names></string-name></person-group>  <article-title>Methylation extends the reach of liquid biopsy in cancer detection</article-title>. <source>Nat. Rev. Clin. Oncol.</source>  <year>2020</year>; <volume>17</volume>:<fpage>655</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">32732909</pub-id>
</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schumacher</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Kapranov</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Kaminsky</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Flanagan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Assadzadeh</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Yau</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Virtanen</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Winegarden</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Cheng</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gingeras</surname>  <given-names>T.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Microarray-based DNA methylation profiling: technology and applications</article-title>. <source>Nucleic Acids Res.</source>  <year>2006</year>; <volume>34</volume>:<fpage>528</fpage>–<lpage>542</lpage>.<pub-id pub-id-type="pmid">16428248</pub-id>
</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noorbakhsh-Sabet</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Zand</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Abedi</surname>  <given-names>V.</given-names></string-name></person-group>  <article-title>Artificial intelligence transforms the future of health care</article-title>. <source>Am. J. Med.</source>  <year>2019</year>; <volume>132</volume>:<fpage>795</fpage>–<lpage>801</lpage>.<pub-id pub-id-type="pmid">30710543</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>D.Y.</given-names></string-name></person-group>  <article-title>Artificial intelligence and computational pathology</article-title>. <source>Lab. Invest.</source>  <year>2021</year>; <volume>101</volume>:<fpage>412</fpage>–<lpage>422</lpage>.<pub-id pub-id-type="pmid">33454724</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jumper</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Evans</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Pritzel</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Green</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Figurnov</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Ronneberger</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Tunyasuvunakool</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Bates</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Zidek</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Potapenko</surname>  <given-names>A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Highly accurate protein structure prediction with AlphaFold</article-title>. <source>Nature</source>. <year>2021</year>; <volume>596</volume>:<fpage>583</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">34265844</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Cai</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Pacheco</surname>  <given-names>P.P.</given-names></string-name>, <string-name><surname>Narrandes</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname>  <given-names>W.</given-names></string-name></person-group>  <article-title>Applications of support vector machine (SVM) learning in cancer genomics</article-title>. <source>Cancer Genomics Proteomics</source>. <year>2018</year>; <volume>15</volume>:<fpage>41</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">29275361</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poirion</surname>  <given-names>O.B.</given-names></string-name>, <string-name><surname>Jing</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Chaudhary</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Huang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Garmire</surname>  <given-names>L.X.</given-names></string-name></person-group>  <article-title>DeepProg: an ensemble of deep-learning and machine-learning models for prognosis prediction using multi-omics data</article-title>. <source>Genome Med.</source>  <year>2021</year>; <volume>13</volume>:<fpage>112</fpage>.<pub-id pub-id-type="pmid">34261540</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Shao</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Huang</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Tang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Ding</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Huang</surname>  <given-names>K.</given-names></string-name></person-group>  <article-title>MOGONET integrates multi-omics data using graph convolutional networks allowing patient classification and biomarker identification</article-title>. <source>Nat. Commun.</source>  <year>2021</year>; <volume>12</volume>:<fpage>3445</fpage>.<pub-id pub-id-type="pmid">34103512</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Xu</surname>  <given-names>R.</given-names></string-name></person-group>  <article-title>Predicting cancer origins with a DNA methylation-based deep neural network model</article-title>. <source>PLoS One</source>. <year>2020</year>; <volume>15</volume>:<fpage>e0226461</fpage>.<pub-id pub-id-type="pmid">32384093</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Modhukur</surname>  <given-names>V.</given-names></string-name>, <string-name><surname>Sharma</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Mondal</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Lawarde</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Kask</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Sharma</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Salumets</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Machine learning approaches to classify primary and metastatic cancers using tissue of origin-based DNA methylation profiles</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>; <volume>13</volume>:<fpage>3768</fpage>.<pub-id pub-id-type="pmid">34359669</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moran</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Martinez-Cardus</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Sayols</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Musulen</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Balana</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Estival-Gonzalez</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Moutinho</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Heyn</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Diaz-Lagares</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>de Moura</surname>  <given-names>M.C.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis</article-title>. <source>Lancet Oncol.</source>  <year>2016</year>; <volume>17</volume>:<fpage>1386</fpage>–<lpage>1395</lpage>.<pub-id pub-id-type="pmid">27575023</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Triche</surname>  <given-names>T.J.</given-names>  <suffix>Jr</suffix></string-name>, <string-name><surname>Laird</surname>  <given-names>P.W.</given-names></string-name>, <string-name><surname>Shen</surname>  <given-names>H.</given-names></string-name></person-group>  <article-title>SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions</article-title>. <source>Nucleic Acids Res.</source>  <year>2018</year>; <volume>46</volume>:<fpage>e123</fpage>.<pub-id pub-id-type="pmid">30085201</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Min</surname>  <given-names>J.L.</given-names></string-name>, <string-name><surname>Hemani</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Davey Smith</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Relton</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Suderman</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>Meffil: efficient normalization and analysis of very large DNA methylation datasets</article-title>. <source>Bioinformatics</source>. <year>2018</year>; <volume>34</volume>:<fpage>3983</fpage>–<lpage>3989</lpage>.<pub-id pub-id-type="pmid">29931280</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fabian Pedregosa</surname>  <given-names>G.V.</given-names></string-name>, <string-name><surname>Gramfort</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Michel</surname>  <given-names>V.</given-names></string-name>, <string-name><surname>Thirion</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Grisel</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Blondel</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Prettenhofer</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Weiss</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Dubourg</surname>  <given-names>V.</given-names></string-name>, <string-name><surname>Vanderplas</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Scikit-learn: machine learning in Python</article-title>. <source>JMLR</source>. <year>2011</year>; <volume>12</volume>:<fpage>2825</fpage>–<lpage>2830</lpage>.</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Legendre</surname>  <given-names>C.R.</given-names></string-name>, <string-name><surname>Demeure</surname>  <given-names>M.J.</given-names></string-name>, <string-name><surname>Whitsett</surname>  <given-names>T.G.</given-names></string-name>, <string-name><surname>Gooden</surname>  <given-names>G.C.</given-names></string-name>, <string-name><surname>Bussey</surname>  <given-names>K.J.</given-names></string-name>, <string-name><surname>Jung</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Waibhav</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Salhia</surname>  <given-names>B.</given-names></string-name></person-group>  <article-title>Pathway implications of aberrant global methylation in adrenocortical cancer</article-title>. <source>PLoS One</source>. <year>2016</year>; <volume>11</volume>:<fpage>e0150629</fpage>.<pub-id pub-id-type="pmid">26963385</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ramalho-Carvalho</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Graca</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Gomez</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Oliveira</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Henrique</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Esteller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Jeronimo</surname>  <given-names>C.</given-names></string-name></person-group>  <article-title>Downregulation of miR-130b∼301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer</article-title>. <source>J. Hematol. Oncol.</source>  <year>2017</year>; <volume>10</volume>:<fpage>43</fpage>.<pub-id pub-id-type="pmid">28166834</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oltra</surname>  <given-names>S.S.</given-names></string-name>, <string-name><surname>Pena-Chilet</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Vidal-Tomas</surname>  <given-names>V.</given-names></string-name>, <string-name><surname>Flower</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Martinez</surname>  <given-names>M.T.</given-names></string-name>, <string-name><surname>Alonso</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Burgues</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Lluch</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Flanagan</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Ribas</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in breast cancer in very young women</article-title>. <source>Sci. Rep.</source>  <year>2018</year>; <volume>8</volume>:<fpage>14373</fpage>.<pub-id pub-id-type="pmid">30258192</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baharudin</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Ishak</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Muhamad Yusof</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Saidin</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Syafruddin</surname>  <given-names>S.E.</given-names></string-name>, <string-name><surname>Wan Mohamad Nazarie</surname>  <given-names>W.F.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>L.H.</given-names></string-name>, <string-name><surname>Ab Mutalib</surname>  <given-names>N.S.</given-names></string-name></person-group>  <article-title>Epigenome-wide DNA methylation profiling in colorectal cancer and normal adjacent colon using infinium human methylation 450K</article-title>. <source>Diagnostics (Basel)</source>. <year>2022</year>; <volume>12</volume>:<fpage>198</fpage>.<pub-id pub-id-type="pmid">35054365</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Court</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Le Boiteux</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Fogli</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Muller-Barthelemy</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Vaurs-Barriere</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Chautard</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Pereira</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Biau</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kemeny</surname>  <given-names>J.L.</given-names></string-name>, <string-name><surname>Khalil</surname>  <given-names>T.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms</article-title>. <source>Genome Res.</source>  <year>2019</year>; <volume>29</volume>:<fpage>1605</fpage>–<lpage>1621</lpage>.<pub-id pub-id-type="pmid">31533980</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Worsham</surname>  <given-names>M.J.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>K.M.</given-names></string-name>, <string-name><surname>Datta</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Stephen</surname>  <given-names>J.K.</given-names></string-name>, <string-name><surname>Chitale</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Gothard</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Divine</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>The biological significance of methylome differences in human papilloma virus associated head and neck cancer</article-title>. <source>Oncol. Lett.</source>  <year>2016</year>; <volume>12</volume>:<fpage>4949</fpage>–<lpage>4956</lpage>.<pub-id pub-id-type="pmid">28101231</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ramalho-Carvalho</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Goncalves</surname>  <given-names>C.S.</given-names></string-name>, <string-name><surname>Graca</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Bidarra</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Pereira-Silva</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Salta</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Godinho</surname>  <given-names>M.I.</given-names></string-name>, <string-name><surname>Gomez</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Esteller</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Costa</surname>  <given-names>B.M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97</article-title>. <source>Clin Epigenetics</source>. <year>2018</year>; <volume>10</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">29599847</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>Y.J.</given-names></string-name>, <string-name><surname>Wu</surname>  <given-names>H.C.</given-names></string-name>, <string-name><surname>Kibriya</surname>  <given-names>M.G.</given-names></string-name>, <string-name><surname>Jasmine</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Ahsan</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Wu</surname>  <given-names>D.P.</given-names></string-name>, <string-name><surname>Siegel</surname>  <given-names>A.B.</given-names></string-name>, <string-name><surname>Remotti</surname>  <given-names>H.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips</article-title>. <source>Epigenetics</source>. <year>2013</year>; <volume>8</volume>:<fpage>34</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">23208076</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirhadi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Tam</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>Q.</given-names></string-name>, <string-name><surname>Moghal</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Pham</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Tong</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Golbourn</surname>  <given-names>B.J.</given-names></string-name>, <string-name><surname>Krieger</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Taylor</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes</article-title>. <source>Nat. Commun.</source>  <year>2022</year>; <volume>13</volume>:<fpage>1811</fpage>.<pub-id pub-id-type="pmid">35383171</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamamoto</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Matsusaka</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Fukuyo</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Rahmutulla</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Matsue</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Kaneda</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis</article-title>. <source>Cancer Med.</source>  <year>2020</year>; <volume>9</volume>:<fpage>7194</fpage>–<lpage>7204</lpage>.<pub-id pub-id-type="pmid">32406600</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>  <given-names>J.L.</given-names></string-name>, <string-name><surname>Jeon</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Seo</surname>  <given-names>E.H.</given-names></string-name>, <string-name><surname>Bae</surname>  <given-names>D.H.</given-names></string-name>, <string-name><surname>Jeong</surname>  <given-names>Y.M.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Bae</surname>  <given-names>J.S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>S.K.</given-names></string-name>, <string-name><surname>Jung</surname>  <given-names>C.K.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>Y.S.</given-names></string-name></person-group>  <article-title>Comprehensive DNA methylation profiling identifies novel diagnostic biomarkers for thyroid cancer</article-title>. <source>Thyroid</source>. <year>2020</year>; <volume>30</volume>:<fpage>192</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">31797753</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trimarchi</surname>  <given-names>M.P.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Groden</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Bundschuh</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Goodfellow</surname>  <given-names>P.J.</given-names></string-name></person-group>  <article-title>Identification of endometrial cancer methylation features using combined methylation analysis methods</article-title>. <source>PLoS One</source>. <year>2017</year>; <volume>12</volume>:<fpage>e0173242</fpage>.<pub-id pub-id-type="pmid">28278225</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Timp</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Bravo</surname>  <given-names>H.C.</given-names></string-name>, <string-name><surname>McDonald</surname>  <given-names>O.G.</given-names></string-name>, <string-name><surname>Goggins</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Umbricht</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Zeiger</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Feinberg</surname>  <given-names>A.P.</given-names></string-name>, <string-name><surname>Irizarry</surname>  <given-names>R.A.</given-names></string-name></person-group>  <article-title>Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors</article-title>. <source>Genome Med.</source>  <year>2014</year>; <volume>6</volume>:<fpage>61</fpage>.<pub-id pub-id-type="pmid">25191524</pub-id>
</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qu</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Sandmann</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Frierson</surname>  <given-names>H.</given-names>  <suffix>Jr</suffix></string-name>, <string-name><surname>Fu</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Fuentes</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Walter</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Okrah</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Rumpel</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Moskaluk</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Lu</surname>  <given-names>S.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter</article-title>. <source>Oncogene</source>. <year>2016</year>; <volume>35</volume>:<fpage>6403</fpage>–<lpage>6415</lpage>.<pub-id pub-id-type="pmid">27270421</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jurmeister</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Scholer</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Arnold</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Klauschen</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Lenze</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Hummel</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Schweizer</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Blaker</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Pfitzner</surname>  <given-names>B.M.</given-names></string-name>, <string-name><surname>Mamlouk</surname>  <given-names>S.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer</article-title>. <source>Mod. Pathol.</source>  <year>2019</year>; <volume>32</volume>:<fpage>855</fpage>–<lpage>865</lpage>.<pub-id pub-id-type="pmid">30723296</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ylitalo</surname>  <given-names>E.B.</given-names></string-name>, <string-name><surname>Thysell</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Landfors</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Brattsand</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Jernberg</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Crnalic</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Widmark</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Hultdin</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Bergh</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Degerman</surname>  <given-names>S.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer</article-title>. <source>Clin Epigenetics</source>. <year>2021</year>; <volume>13</volume>:<fpage>133</fpage>.<pub-id pub-id-type="pmid">34193246</pub-id>
</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moss</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Magenheim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Neiman</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Zemmour</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Loyfer</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Korach</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Samet</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Maoz</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Druid</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Arner</surname>  <given-names>P.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease</article-title>. <source>Nat. Commun.</source>  <year>2018</year>; <volume>9</volume>:<fpage>5068</fpage>.<pub-id pub-id-type="pmid">30498206</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hlady</surname>  <given-names>R.A.</given-names></string-name>, <string-name><surname>Zhao</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Pan</surname>  <given-names>X.</given-names></string-name>, <string-name><surname>Yang</surname>  <given-names>J.D.</given-names></string-name>, <string-name><surname>Ahmed</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Antwi</surname>  <given-names>S.O.</given-names></string-name>, <string-name><surname>Giama</surname>  <given-names>N.H.</given-names></string-name>, <string-name><surname>Patel</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Roberts</surname>  <given-names>L.R.</given-names></string-name>, <string-name><surname>Liu</surname>  <given-names>C.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA</article-title>. <source>Theranostics</source>. <year>2019</year>; <volume>9</volume>:<fpage>7239</fpage>–<lpage>7250</lpage>.<pub-id pub-id-type="pmid">31695765</pub-id>
</mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordevicius</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Krisciunas</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Groot</surname>  <given-names>D.E.</given-names></string-name>, <string-name><surname>Yip</surname>  <given-names>S.M.</given-names></string-name>, <string-name><surname>Susic</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Kwan</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Kustra</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Joshua</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>Chi</surname>  <given-names>K.N.</given-names></string-name>, <string-name><surname>Petronis</surname>  <given-names>A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients</article-title>. <source>Clin. Cancer Res.</source>  <year>2018</year>; <volume>24</volume>:<fpage>3317</fpage>–<lpage>3324</lpage>.<pub-id pub-id-type="pmid">29615462</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silva</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Moran</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Russell</surname>  <given-names>N.M.</given-names></string-name>, <string-name><surname>Fahey</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Vlajnic</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Manecksha</surname>  <given-names>R.P.</given-names></string-name>, <string-name><surname>Finn</surname>  <given-names>S.P.</given-names></string-name>, <string-name><surname>Brennan</surname>  <given-names>D.J.</given-names></string-name>, <string-name><surname>Gallagher</surname>  <given-names>W.M.</given-names></string-name>, <string-name><surname>Perry</surname>  <given-names>A.S.</given-names></string-name></person-group>  <article-title>Evaluating liquid biopsies for methylomic profiling of prostate cancer</article-title>. <source>Epigenetics</source>. <year>2020</year>; <volume>15</volume>:<fpage>715</fpage>–<lpage>727</lpage>.<pub-id pub-id-type="pmid">32000564</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silva</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Moran</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Baird</surname>  <given-names>A.M.</given-names></string-name>, <string-name><surname>O’Rourke</surname>  <given-names>C.J.</given-names></string-name>, <string-name><surname>Finn</surname>  <given-names>S.P.</given-names></string-name>, <string-name><surname>McDermott</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Watson</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Gallagher</surname>  <given-names>W.M.</given-names></string-name>, <string-name><surname>Brennan</surname>  <given-names>D.J.</given-names></string-name>, <string-name><surname>Perry</surname>  <given-names>A.S.</given-names></string-name></person-group>  <article-title>Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer</article-title>. <source>Clin Epigenetics</source>. <year>2021</year>; <volume>13</volume>:<fpage>168</fpage>.<pub-id pub-id-type="pmid">34454584</pub-id>
</mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ehrlich</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>DNA hypomethylation in cancer cells</article-title>. <source>Epigenomics</source>. <year>2009</year>; <volume>1</volume>:<fpage>239</fpage>–<lpage>259</lpage>.<pub-id pub-id-type="pmid">20495664</pub-id>
</mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Zhao</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Wei</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Su</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Liu</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Zhang</surname>  <given-names>Y.</given-names></string-name></person-group>  <article-title>The identification of specific methylation patterns across different cancers</article-title>. <source>PLoS One</source>. <year>2015</year>; <volume>10</volume>:<fpage>e0120361</fpage>.<pub-id pub-id-type="pmid">25774687</pub-id>
</mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sammut</surname>  <given-names>S.J.</given-names></string-name>, <string-name><surname>Crispin-Ortuzar</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Chin</surname>  <given-names>S.F.</given-names></string-name>, <string-name><surname>Provenzano</surname>  <given-names>E.</given-names></string-name>, <string-name><surname>Bardwell</surname>  <given-names>H.A.</given-names></string-name>, <string-name><surname>Ma</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Cope</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Dariush</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Dawson</surname>  <given-names>S.J.</given-names></string-name>, <string-name><surname>Abraham</surname>  <given-names>J.E.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Multi-omic machine learning predictor of breast cancer therapy response</article-title>. <source>Nature</source>. <year>2022</year>; <volume>601</volume>:<fpage>623</fpage>–<lpage>629</lpage>.<pub-id pub-id-type="pmid">34875674</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>C.Y.</given-names></string-name>, <string-name><surname>Wang</surname>  <given-names>Z.H.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>H.Y.</given-names></string-name>, <string-name><surname>Guan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>Y.X.</given-names></string-name>, <string-name><surname>Fang</surname>  <given-names>J.Y.</given-names></string-name></person-group>  <article-title>Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer</article-title>. <source>Sci. Rep.</source>  <year>2015</year>; <volume>5</volume>:<fpage>8473</fpage>.<pub-id pub-id-type="pmid">25683757</pub-id>
</mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benjamin</surname>  <given-names>D.I.</given-names></string-name>, <string-name><surname>Louie</surname>  <given-names>S.M.</given-names></string-name>, <string-name><surname>Mulvihill</surname>  <given-names>M.M.</given-names></string-name>, <string-name><surname>Kohnz</surname>  <given-names>R.A.</given-names></string-name>, <string-name><surname>Li</surname>  <given-names>D.S.</given-names></string-name>, <string-name><surname>Chan</surname>  <given-names>L.G.</given-names></string-name>, <string-name><surname>Sorrentino</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bandyopadhyay</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Cozzo</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Ohiri</surname>  <given-names>A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness</article-title>. <source>ACS Chem. Biol.</source>  <year>2014</year>; <volume>9</volume>:<fpage>1340</fpage>–<lpage>1350</lpage>.<pub-id pub-id-type="pmid">24738946</pub-id>
</mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rao</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Xu</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Fu</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Cha</surname>  <given-names>J.Y.</given-names></string-name>, <string-name><surname>Gadalla</surname>  <given-names>M.M.</given-names></string-name>, <string-name><surname>Xu</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Barrow</surname>  <given-names>J.C.</given-names></string-name>, <string-name><surname>Snyder</surname>  <given-names>S.H.</given-names></string-name></person-group>  <article-title>Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>  <year>2015</year>; <volume>112</volume>:<fpage>1773</fpage>–<lpage>1778</lpage>.<pub-id pub-id-type="pmid">25617365</pub-id>
</mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindblad</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Ye</surname>  <given-names>W.</given-names></string-name>, <string-name><surname>Lindgren</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Lagergren</surname>  <given-names>J.</given-names></string-name></person-group>  <article-title>Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates</article-title>. <source>Ann. Surg.</source>  <year>2006</year>; <volume>243</volume>:<fpage>479</fpage>–<lpage>485</lpage>.<pub-id pub-id-type="pmid">16552198</pub-id>
</mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Businello</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Fassan</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Degasperi</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Traverso</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Scarpa</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Angriman</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Kotsafti</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Castagliuolo</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Sbaraglia</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Bardini</surname>  <given-names>R.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Esophageal squamous cell carcinoma metachronous to head and neck cancers</article-title>. <source>Pathol. Res. Pract.</source>  <year>2021</year>; <volume>219</volume>:<fpage>153346</fpage>.<pub-id pub-id-type="pmid">33545655</pub-id>
</mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holm</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Hegardt</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Staaf</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Vallon-Christersson</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Jonsson</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Olsson</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Borg</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Ringner</surname>  <given-names>M.</given-names></string-name></person-group>  <article-title>Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns</article-title>. <source>Breast Cancer Res.</source>  <year>2010</year>; <volume>12</volume>:<fpage>R36</fpage>.<pub-id pub-id-type="pmid">20565864</pub-id>
</mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakagawa</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Kurokawa</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Mima</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Imamoto</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Mizokami</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Kondo</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Okamoto</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Misawa</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Hanazawa</surname>  <given-names>T.</given-names></string-name>, <string-name><surname>Kaneda</surname>  <given-names>A.</given-names></string-name></person-group>  <article-title>DNA methylation and HPV-associated head and neck cancer</article-title>. <source>Microorganisms</source>. <year>2021</year>; <volume>9</volume>:<fpage>801</fpage>.<pub-id pub-id-type="pmid">33920277</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
